We encourage you to republish this article online and in print, it’s free under our creative commons attribution license, but please follow some simple guidelines:
  1. You have to credit our authors.
  2. You have to credit SciDev.Net — where possible include our logo with a link back to the original article.
  3. You can simply run the first few lines of the article and then add: “Read the full article on SciDev.Net” containing a link back to the original article.
  4. If you want to also take images published in this story you will need to confirm with the original source if you're licensed to use them.
  5. The easiest way to get the article on your site is to embed the code below.
For more information view our media page and republishing guidelines.

The full article is available here as HTML.

Press Ctrl-C to copy

Cervical cancer hits the poor hardest — 80 per cent of the deaths it causes are in developing countries.

Meanwhile, the disease, which is triggered by the human papilloma virus (HPV), is in decline in the West, vanquished by cervical smear tests.

Two new, unusually successful vaccines have entered phase III clinical trials and offer the hope that infection rates will decline in developing countries.

In this article in Science, Jon Cohen chronicles the development of the vaccines by Merck in the United States and GlaxoSmithKline in Belgium, and looks beyond the lab at the dilemmas facing researchers and poor countries alike.

One worry shared by many researchers is that the vaccines could take years to reach developing countries. In addition, the vaccines do not cover every type of HPV, so they will fail to work in about 30 per cent of cases. However, researchers believe the benefits outweigh the concerns.

Link to full article in Science

Related topics